8 Annual Oncology Economics Forum Access to Innovative Cancer Therapies in 2013

Access to Innovative Cancer Therapies in 2013
8th Annual Oncology Economics Forum
Issues, Challenges & Opportunities Related to Healthcare Reform,
Pricing, Reimbursement, and Payer Coverage Decisions in Oncology
June 18 & 19, 2013 ● Hyatt Regency Philadelphia at Penn’s Landing ● Philadelphia, PA
Day One Agenda - Tuesday, June 18, 2013
7:30 – 8:30
Registration/Check-In and Continental Breakfast
8:30 - 8:35
Welcome & Opening Remarks by Forum Co-Chairs
8:35 – 9:15
Legislative Update and Healthcare Reform Developments Impacting Access
to Cancer Care
Joseph S. Bailes, MD
Medical Oncologist and National Authority on Healthcare Policy
The Healthcare Agenda and the Implications for Cancer Care in
2013 and Beyond
Sequestration and the Outlook for the Oncology Practice
Legislative and Regulatory Update - Exploring Legislative and
Regulatory Proposals that Have the Potential to Impact
Manufacturers, Pharmacies, PBMs and Health Plans
Oncology Coverage and Access Issues
9:15 – 10:00
Health Insurance Exchanges and the Impact of Medicaid Expansion on
Biotech/Pharma
Caleb DesRosiers, JD
Counsel, Health Care Regulatory and Government Strategies Practice,
Foley Hoag, LLP
With increasing uncertainty created by Medicaid expansion, where
do individual states stand and what are the different types of
service that will be needed?
Competitive opportunities and/or challenges that could result from
states’ decisions
Understanding the importance of effective relationships with state
or federal policy makers
10:00 – 10:30
Morning Break
10:30 – 11:15
Oral Chemotherapy Parity Legislation in the States: The Interaction of
Patient Protections and Essential Health Benefits
Tim Dube
Associate Director, State Public Policy, Genentech
Background on oral chemotherapy parity legislative efforts before
the ACA
Review of federal essential health benefits (EHB) rules and the
language on state mandated benefits
Review of current state legislative efforts and why advocates have
to be mindful of the interaction with EHB
www.conferagroup.com
●
Tel/ 704.849.6934
1
Access to Innovative Cancer Therapies in 2013
8th Annual Oncology Economics Forum
Day One Agenda continued - Tuesday, June 18, 2013
11:15 – 12:00
340B Drug Discount Program Impact on Cancer Care
Aaron Vandervelde
Principal, Health Analytics, Berkeley Research Group
Recent and upcoming activities from HRSA and OPA
Need for HRSA to clarify Patient Definition
Oversight and compliance considerations, including Medicaid carve
in possibilities
Oncology site and contract pharmacy expansion
12:00 – 12:30
Health Reform and the Impact on Cancer Care in 2013
How are new policies affecting access to cancer care?
What can oncology stakeholders expect in 2013, 2014, and beyond?
Joseph S. Bailes, MD
Medical Oncologist and National Authority on Healthcare Policy
Caleb DesRosiers, JD, MPA,
Counsel, Health Care Regulatory an Government Strategies Practice,
Foley Hoag, LLP
Tim Dube
Associate Director, State Public Policy, Genentech
Aaron Vandervelde
Principal, Health Analytics, Berkeley Research Group
_____________________________________________________________________________________________
12:30 – 1:30
Luncheon
_____________________________________________________________________________________________
1:30 – 2:15
Examining Shifts in Site of Care and Provider Consolidation
Donna Bowers, JD, RHIA, CHP
Senior Vice President, Cancer Service Line, McKesson Specialty Health
Defining the cancer treatment setting: community practices vs. hospitals,
integrated cancer networks, and academic institutions
Who is “at risk” and how does a community practice remain
efficient?
Overview of oncology practice alignments and consolidations with
comparisons of successes and failures
Key considerations to keep in mind before joining a hospital
2:15 – 3:00
Practical Implications of Clinical Pathways in the Oncology Practice
Michael Forsyth, RPh
Manager, Pharmacy Services, Rocky Mountain Cancer Center
Aligning treatment decisions with clinical pathways – quality of care
considerations
Assessing the economic impact of clinical pathway decisions on the
practice
Integration of clinical pathways with EMR and IT systems
Impact of clinical pathways on the drug selection and purchasing
process
www.conferagroup.com
●
Tel/ 704.849.6934
2
Access to Innovative Cancer Therapies in 2013
8th Annual Oncology Economics Forum
One Agenda continued - Tuesday, June 18, 2013
3:00 – 3:30
Afternoon Break
3:30 – 4:00
A Closer Look at an Oncology Clinical Decision Support Platform and the
Cancer Treatment Decision Process
William Flood, MD
Chief Medical Officer, eviti
Aligning clinical pathways with evidence-based outcomes and
reimbursement objectives
The impact of a pathway-based treatment plan review and selection
process on the oncology practice
Examination of a current oncology clinical decision support
platform and the improvement of patient outcomes
4:00 – 4:45
Provider Consolidation, Pathways, Coverage Determinations – A Discussion
of the Key Issues Impacting Access to Cancer Care
What are the key trends and issues regarding clinical pathways and
what is expected in 2013 and beyond?
What is on the horizon regarding new treatment platforms?
What are the implications for pharma and what role does industry
play moving forward?
4:45 – 5:00
Closing Comments
5:00
Forum Adjourns for Day One
5:00 – 6:30
Faculty & Attendee Reception
Day Two Agenda - Wednesday, June 19, 2013
7:30 – 8:30
Continental Breakfast
8:30 – 8:45
Opening Remarks and Review of Day One
8:45 – 9:45
Payer Initiatives in the Management of Oncology
Joseph S. Bailes, MD
Medical Oncologist and National Authority on Healthcare Policy
Michael A. Kolodziej, MD, FACP
National Medical Director of Oncology Strategy, Office of the Chief Medical
Officer, Aetna
Bryan Loy, MD
Market Medical Officer, Humana - invited
Payer perspectives regarding emerging delivery-care models and
collaboration efforts with providers
Past and current MCO priorities in the specialty drug category
Trends impacting payer coverage decisions for oncology
www.conferagroup.com
●
Tel/ 704.849.6934
3
Access to Innovative Cancer Therapies in 2013
8th Annual Oncology Economics Forum
Day Two Agenda continued - Wednesday, June 19, 2013
9:45 – 10:15
Issues & Trends Impacting the Oral Oncology Drug Marketplace
Jeff Patton, MD, Founder & CEO, Rain Tree Oncology - invited
Oral oncology therapy pilot programs and collaborative efforts
Potential payer initiatives in managing the medical benefit versus
pharmacy benefit
Comparison of specialty pharmacy versus onsite dispensing in
oncology
10:15 – 10:45
Morning Break
10:45 – 11:45
Market Access Challenges and Opportunities for Oncology Drugs
Coline David
Principal, Specialty Drug Market Access
Peter W. Davis
Partner, Epiphany Partners
Outline of reimbursement and pricing trends & exploration of cost
controls
Regulation of oncology drugs in other markets & outline of global
reimbursement and pricing trends
Opportunities in emerging markets
11:45 – 12:00
Closing Comments
12:00
Forum Adjourns
www.conferagroup.com
●
Tel/ 704.849.6934
4